key: cord-0926552-mfqjk0hu authors: Chen, Xiuju; Wang, Bin; Li, Xiaoxin title: Acute-onset Vogt-Koyanagi-Harada-like uveitis following Covid-19 inactivated virus vaccination date: 2022-02-09 journal: Am J Ophthalmol Case Rep DOI: 10.1016/j.ajoc.2022.101404 sha: f48b471e21d2e06afe6fd9704261845311c760b7 doc_id: 926552 cord_uid: mfqjk0hu PURPOSE: We report a case of a 19-year-old male who presented with bilateral Vogt-Koyanagi-Harada (VKH)-like panuveitis following an injection of an inactivated Covid-19 vaccine. OBSERVATIONS: A 19-year-old male was referred to our clinic with a 2-week history of blurred vision on both eyes and headaches, 12 hours following the administration of the first dose of an inactivated Covid-19 virus vaccine (Sinovac). He denied any past ocular or medical history. Clinical examination and multimodal imaging tests identified serous retinal detachment and choroidal thickening posteriorly and deep yellow foci in the far peripheral retina. Aqueous humor analysis ruled out viral and bacterial infection including Covid-19, but demonstrated an elevated interleukin-6 level. A workup ruled out systemic infection or autoimmune disease. Although the patient received a single positive T-SPOT result, no other clinical evidence supported active tuberculosis infection. Non-infectious panuveitis was diagnosed and treated with periocular steroids that quickly resolved the serous retinal detachment. CONCLUSIONS AND IMPORTANCE: This is the first report of VKH-like uveitis following an inactivated Covid-19 vaccine, with aqueous humor analysis ruling out viral or bacterial infection and demonstrating an elevated interleukin-6 level. Though rare, VKH-like uveitis may be associated with administration of an inactivated Covid-19 vaccine. The Covid-19 pandemic has promoted vaccine development at a fast pace. There are currently over 10 vaccines developed and approved for use within 2 years of the pandemic. 1 VKH-like uveitis is a very rare adverse event of vaccination, and only several cases have been reported worldwide following vaccines against yellow fever, influenza, hepatitis B, and human papilloma virus (HPV), as well as following administration of the bacille Calmette-Guerin (BCG) vaccine. [10] [11] [12] [13] Recently, cases of VKH disease following Covid-19 mRNA and adenovirus vector vaccine have been reported. 14 We report a case of bilateral VKH-like disease following an inactivated Covid-19 virus vaccine. After initial evaluation, the patient was treated for non-infectious panuveitis with periocular injections of triamcinolone acetonide 40 mg in each eye. Subretinal fluid decreased quickly within two days of treatment, (Figure 4 ). Blurred vision resolved in five days, and the patient has had no recurrent ocular disturbance through four months of follow-up. Our case highlights the possibility of panuveitis following administration of an inactivated Covid-19 vaccine. While the rapid resolution of the disease with excellent visual recovery reassured us that this type of adverse event could be transient and treatable, the mechanism underlying vaccine-associated uveitis is unclear, and it is difficult to prove causality in these rare cases. Commonly proposed mechanisms of inflammation may be induced by the adjuvants that are routinely used in inactivated or subunit vaccines to enhance the immunogenicity of the virus. 15 The autoimmunity has been classified as Shoenfeld syndrome that is often accompanied by arthralgia and fatigue, typically occurring in patients with an autoimmune disorder. Like our case, VKH-like uveitis is reported to J o u r n a l P r e -p r o o f occur mostly in association with the inactivated vaccinates against yellow fever, influenza, BCG and HPV. [10] [11] [12] [13] However, there are reported VKH diseases related to Pfizer mRNA as well as the adenovirus vector vaccine (AZD1222). Reactivation of VKH disease after the second dose of of Pfizer mRNA (BNT162b2) has also been reported 8 . Both of these vaccines do not utilize an additional adjuvant. 8 14 Due to the similar phenotype of uveitis despite a different type of vaccine, antigen mimicry from the virus could be a potential trigger. In this case, additional aqueous humor analysis ruled out intraocular infection and demonstrated the inflammatory status, with prominent elevated IL-6. More analyses are needed to elucidate the mechanism of this reaction. Although we called this case VKH-like uveitis due to the inflammatory nature and multiple serous detachments of the neurosensory retina, the OCT did not show features like subretinal septa or folds of the retinal pigmented epithelium as are often seen in VKH. 16 The FA of this patient showed mild and even hyperfluorescence in the area of retinal detachment, unlike multifocal leaks at the level of the retinal pigment epithelium that pool into the sub-neurosensory retinal space in VKH syndrome. 17 18 There are some deep focal lesions in the midperiphery in both eyes that are consistent with the hyperfluorescent spot on the FA. However, there are no positive findings in the AF or OCT, distinguishing this condition from MEWDS. [19] [20] [21] Given the atypical combined features in this case, the close temporal relationship between the symptom onset and the vaccination, the immunocompetent status of this patient, no evidence of infection, and J o u r n a l P r e -p r o o f quickly improvement in vision following treatment with steroids, the vaccine can be categorized as a probable trigger, according to the Naranjo adverse event probability scale 22 . Nevertheless, a causal relationship cannot be established from this single case report. As the urge for a vaccination against Covid-19 continues, potential ocular adverse events should be reported in detail to increase awareness among the medical community. J o u r n a l P r e -p r o o f Written informed consent was obtained from the patient for publication of this case report and use of any accompanying images. No funding or grant support was provided for this report. All the authors have no financial disclosures: XJC BW XXL All the authors attest that they meet the current ICMJE criteria for authorship. None. J o u r n a l P r e -p r o o f Ocular Adverse Events After COVID-19 Vaccination Uveitis following the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association Panuveitis following Vaccination for COVID-19 Acute Uveitis following COVID-19 Vaccination Acute-onset central serous retinopathy after immunization with COVID-19 mRNA vaccine Bilateral Multifocal Choroiditis following COVID-19 Vaccination Acute Macular Neuroretinopathy following Coronavirus Disease 2019 Vaccination Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination Association of Ocular Adverse Events With Inactivated COVID-19 Vaccination in Patients in Abu Dhabi Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis Vogt-Koyanagi-Harada Syndrome following influenza vaccination Vogt-Koyanagi-Harada Disease Associated with Hepatitis B Vaccination Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome) -An update Tomographic features of serous retinal detachment with multilobular dye pooling in acute Vogt-Koyanagi-Harada disease Frequency of distinguishing clinical features in Vogt-Koyanagi-Harada disease Clinical spectrum and management options in Vogt-Koyanagi-Harada disease Spectral domain optical coherence tomography and autofluorescence in a case of acute posterior multifocal placoid pigment epitheliopathy mimicking Vogt-Koyanagi-Harada disease: case report and review of literature Acute posterior multifocal placoid pigment epitheliopathy Fundus autofluorescence imaging of the white dot syndromes A method for estimating the probability of adverse drug reactions